Logo image of ORGS

ORGENESIS INC (ORGS) Stock Fundamental Analysis

NASDAQ:ORGS - Nasdaq - US68619K2042 - Common Stock - Currency: USD

2.11  -1.13 (-34.84%)

After market: 2.25 +0.14 (+6.64%)

Fundamental Rating

1

Overall ORGS gets a fundamental rating of 1 out of 10. We evaluated ORGS against 551 industry peers in the Biotechnology industry. ORGS has a bad profitability rating. Also its financial health evaluation is rather negative. ORGS has a valuation in line with the averages, but on the other hand it scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year ORGS has reported negative net income.
In the past year ORGS has reported a negative cash flow from operations.
ORGS had negative earnings in 4 of the past 5 years.
ORGS had a negative operating cash flow in each of the past 5 years.
ORGS Yearly Net Income VS EBIT VS OCF VS FCFORGS Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 -20M -40M -60M -80M

1.2 Ratios

ORGS has a Return On Assets of -124.09%. This is amonst the worse of the industry: ORGS underperforms 81.71% of its industry peers.
Industry RankSector Rank
ROA -124.09%
ROE N/A
ROIC N/A
ROA(3y)-142.32%
ROA(5y)-90.32%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ORGS Yearly ROA, ROE, ROICORGS Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 1K 2K 3K

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for ORGS so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ORGS Yearly Profit, Operating, Gross MarginsORGS Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 -2K -4K -6K -8K -10K

More info and screens

0

2. Health

2.1 Basic Checks

ORGS does not have a ROIC to compare to the WACC, probably because it is not profitable.
ORGS has more shares outstanding than it did 1 year ago.
The number of shares outstanding for ORGS has been increased compared to 5 years ago.
ORGS has a worse debt/assets ratio than last year.
ORGS Yearly Shares OutstandingORGS Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 10M 20M 30M
ORGS Yearly Total Debt VS Total AssetsORGS Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 20M 40M 60M 80M

2.2 Solvency

Based on the Altman-Z score of -12.18, we must say that ORGS is in the distress zone and has some risk of bankruptcy.
ORGS has a worse Altman-Z score (-12.18) than 79.93% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -12.18
ROIC/WACCN/A
WACC7.32%
ORGS Yearly LT Debt VS Equity VS FCFORGS Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 20M -20M 40M -40M -60M

2.3 Liquidity

ORGS has a Current Ratio of 0.07. This is a bad value and indicates that ORGS is not financially healthy enough and could expect problems in meeting its short term obligations.
ORGS has a worse Current ratio (0.07) than 98.76% of its industry peers.
A Quick Ratio of 0.07 indicates that ORGS may have some problems paying its short term obligations.
ORGS has a worse Quick ratio (0.07) than 98.76% of its industry peers.
Industry RankSector Rank
Current Ratio 0.07
Quick Ratio 0.07
ORGS Yearly Current Assets VS Current LiabilitesORGS Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 20M 40M 60M

More info and screens

0

3. Growth

3.1 Past

ORGS shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -125.83%.
ORGS shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -98.14%.
ORGS shows a very negative growth in Revenue. Measured over the last years, the Revenue has been decreasing by -50.95% yearly.
EPS 1Y (TTM)-125.83%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-52.75%
Revenue 1Y (TTM)-98.14%
Revenue growth 3Y-58.93%
Revenue growth 5Y-50.95%
Sales Q2Q%-96.47%

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y190.48%
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year39.76%
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
ORGS Yearly Revenue VS EstimatesORGS Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M
ORGS Yearly EPS VS EstimatesORGS Yearly EPS VS EstimatesYearly EPS VS Estimates 2019 2020 2021 2022 2023 2024 0 0.5 -0.5 -1 -1.5

More info and screens

4

4. Valuation

4.1 Price/Earnings Ratio

ORGS reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
With a Price/Forward Earnings ratio of 3.39, the valuation of ORGS can be described as very cheap.
ORGS's Price/Forward Earnings ratio is rather cheap when compared to the industry. ORGS is cheaper than 99.29% of the companies in the same industry.
Compared to an average S&P500 Price/Forward Earnings ratio of 34.04, ORGS is valued rather cheaply.
Industry RankSector Rank
PE N/A
Fwd PE 3.39
ORGS Price Earnings VS Forward Price EarningsORGS Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ORGS Per share dataORGS EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -1 -2 -3 -4 -5

4.3 Compensation for Growth

ORGS's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

ORGS does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ORGENESIS INC

NASDAQ:ORGS (10/18/2024, 8:00:02 PM)

After market: 2.25 +0.14 (+6.64%)

2.11

-1.13 (-34.84%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)08-13 2024-08-13/bmo
Earnings (Next)11-11 2024-11-11/bmo
Inst Owners3.18%
Inst Owner Change0%
Ins Owners790.6%
Ins Owner Change0%
Market Cap10.06M
Analysts82.86
Price Target6.12 (190.05%)
Short Float %0.22%
Short Ratio0.05
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-98.66%
Min Revenue beat(2)-98.85%
Max Revenue beat(2)-98.46%
Revenue beat(4)0
Avg Revenue beat(4)-98.92%
Min Revenue beat(4)-99.2%
Max Revenue beat(4)-98.46%
Revenue beat(8)2
Avg Revenue beat(8)-49.23%
Revenue beat(12)4
Avg Revenue beat(12)-34.26%
Revenue beat(16)6
Avg Revenue beat(16)-8.82%
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 3.39
P/S 15.2
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-1.17
EYN/A
EPS(NY)0.62
Fwd EY29.49%
FCF(TTM)-2.63
FCFYN/A
OCF(TTM)-2.52
OCFYN/A
SpS0.14
BVpS-3.25
TBVpS-5.33
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -124.09%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-142.32%
ROA(5y)-90.32%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover0.02
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 34.15%
Cap/Sales 75.68%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.07
Quick Ratio 0.07
Altman-Z -12.18
F-Score2
WACC7.32%
ROIC/WACCN/A
Cap/Depr(3y)394.92%
Cap/Depr(5y)321.88%
Cap/Sales(3y)150.7%
Cap/Sales(5y)156.63%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-125.83%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-52.75%
EPS Next Y190.48%
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-98.14%
Revenue growth 3Y-58.93%
Revenue growth 5Y-50.95%
Sales Q2Q%-96.47%
Revenue Next Year39.76%
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-231.92%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y59.18%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y39.92%
OCF growth 3YN/A
OCF growth 5YN/A